Literature DB >> 3102963

Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions.

K Schimpf, P M Mannucci, W Kreutz, H H Brackmann, G Auerswald, N Ciavarella, J Mösseler, V DeRosa, B Kraus, C Brueckmann.   

Abstract

Post-transfusion hepatitis is frequent among patients with hemophilia who are treated with concentrated factor VIII prepared from pooled plasma, especially if it is obtained from paid donors. In 26 patients with hemophilia A or von Willebrand's disease who had not been treated with blood or any blood product and hence were highly susceptible to the development of post-transfusion hepatitis, we infused 32 batches of a factor VIII concentrate that had been produced from large pools of human plasma (collected from paid plasmapheresis donors) and then heated in solution at 60 degrees C for 10 hours before final lyophilization. Patients were examined clinically and serologically over a period of 12 months after the first infusion of the pasteurized concentrate. Neither hepatitis nor serologic signs of other viral infections were observed. The hemostatic effectiveness of the concentrate appeared to be satisfactory relative to untreated concentrates.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3102963     DOI: 10.1056/NEJM198704093161505

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  13 in total

1.  Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III.

Authors:  S Lethagen; E Berntorp; I M Nilsson
Journal:  Ann Hematol       Date:  1992-12       Impact factor: 3.673

2.  Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Authors:  Angelo Agostoni; Emel Aygören-Pürsün; Karen E Binkley; Alvaro Blanch; Konrad Bork; Laurence Bouillet; Christoph Bucher; Anthony J Castaldo; Marco Cicardi; Alvin E Davis; Caterina De Carolis; Christian Drouet; Christiane Duponchel; Henriette Farkas; Kálmán Fáy; Béla Fekete; Bettina Fischer; Luigi Fontana; George Füst; Roberto Giacomelli; Albrecht Gröner; C Erik Hack; George Harmat; John Jakenfelds; Mathias Juers; Lajos Kalmár; Pál N Kaposi; István Karádi; Arianna Kitzinger; Tímea Kollár; Wolfhart Kreuz; Peter Lakatos; Hilary J Longhurst; Margarita Lopez-Trascasa; Inmaculada Martinez-Saguer; Nicole Monnier; István Nagy; Eva Németh; Erik Waage Nielsen; Jan H Nuijens; Caroline O'grady; Emanuela Pappalardo; Vincenzo Penna; Carlo Perricone; Roberto Perricone; Ursula Rauch; Olga Roche; Eva Rusicke; Peter J Späth; George Szendei; Edit Takács; Attila Tordai; Lennart Truedsson; Lilian Varga; Beáta Visy; Kayla Williams; Andrea Zanichelli; Lorenza Zingale
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

3.  Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII C.

Authors:  J M Lusher
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

Review 4.  Hemophilia treatment in historical perspective: a review of medical and social developments.

Authors:  F R Rosendaal; C Smit; E Briët
Journal:  Ann Hematol       Date:  1991-02       Impact factor: 3.673

5.  HIV transmission to patients with hemophilia by heat-treated, donor-screened factor concentrate.

Authors:  R S Remis; M V O'Shaughnessy; C Tsoukas; G H Growe; M T Schechter; R W Palmer; D N Lawrence
Journal:  CMAJ       Date:  1990-06-01       Impact factor: 8.262

Review 6.  Viral safety issues: plasma-derived factor VIII.

Authors:  E Berntorp
Journal:  Ann Hematol       Date:  1994       Impact factor: 3.673

7.  Safety trial of heated factor VIII concentrate (8Y).

Authors:  K J Pasi; F G Hill
Journal:  Arch Dis Child       Date:  1989-10       Impact factor: 3.791

8.  Evidence for persistent hepatitis C virus (HCV) infection in hemophiliacs.

Authors:  J P Allain; S H Dailey; Y Laurian; D S Vallari; A Rafowicz; S M Desai; S G Devare
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

Review 9.  Prophylaxis of bleeding episodes in patients with von Willebrand's disease.

Authors:  Augusto B Federici
Journal:  Blood Transfus       Date:  2008-09       Impact factor: 3.443

10.  In vivo recovery and half-life time of a steam-treated factor IX concentrate in hemophilia B patients. The influence of reagents and standards.

Authors:  M Köhler; E Seifried; P Hellstern; G Pindur; C Miyashita; S Mörsdorf; F Fasco; E Wenzel
Journal:  Blut       Date:  1988-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.